( ment sites is highlyencouraging. SPC...)Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research,Health

SPC2996 is currently in international human Phase I/II studies in CLL. Results of the first clinical study will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology, June 1-5.

- ENDS -

For further information, please contact:

Dr. Keith McCullagh

President & CEO, Santaris Pharma,

Tel: +45 4517 9819, Cell:+44 7939 573548, km@santaris.com km@santaris.com>

For media relations, contact:

Annabel Entress, a.entress@northbankcommunications.com a.entress@northbankcommunications.com> , +44 (0)20 7268 3002

Adam Michael, a.michael@northbankcommunications.com a.michael@northbankcommunications.com> , +44 (0)20 7268 3002

Notes to editors

Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults in western Europe and North America, new cases occurring at an annual incidence of 3 to 5 per 100,000 persons in the population. The condition occurs primarily in older people with a median age at diagnosis of 66 years. Men are twice as likely as women to develop the disease. The clinical course of the condition varies widely with some patients showing rapid disease progression and early death, despite intensive chemotherapy, and others surviving for decades without any treatment. CLL is characterised by excessive numbers of functionally incompetent long-lived B-lymphocytes (small white blood cells) circulating in the blood, sometimes also causing swelling of lymph nodes, spleen and other organs. The failure of these cancerous B-CLL cells to die is generally thought to be due at least in part to over expression of the Bcl-2 gene characteristic of the disease.

About Bcl-2